Abstract
Objective: Medullary thyroid carcinoma (MTC) frequently occurs in a sporadic form, but a substantial number of cases are hereditary and appear as part of the multiple endocrine neoplasia type 2 (MEN2) syndromes. Germline mutations in ret proto-oncogene have been shown to be the underlying cause of MEN2 syndromes. Design: We carried out a multi-center study that aimed to perform mutational analysis of so called sporadic MTC patients. Methods: Fifty-six MTC patients verified by histopathologic examination were subjected to genetic analysis. Exon 10, 11, 13, 14, 15 and 16 of the ret gene were analyzed by DNA sequencing and restriction enzyme digestion method. Results: Among 56 apparently sporadic MTC patients, we identified 6 (10.7%) ret germline mutation carriers. Three individuals carried mutations at codon 634 in exon 11, one at codon 618 in exon 10, and two at codon 804 in exon 14. Identification of the predisposition gene mutation has allowed DNA-based strategy for direct mutation detection in patients with apparently sporadic MTCs. A substantial number of patients with apparently sporadic MTC carried germline mutations and 50% of their first degree relatives are expected to have or to develop MTC and/or other endocrine tumors. Conclusions: These results indicate the importance of careful genetic surveillance of any patient with apparently sporadic MTCs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Marsh DJ, Learoyd DL, Robinson BG. Medullarythyroid carcinoma: recent advances and management update. Thyroid 1995, 5: 407–24.
Raue F, Frank-Raue K, Grauer A. Multiple endocrine neoplasia type 2, clinical features and screening. Endocrinol Metab Clin North Am 1994, 23: 137–56.
Mulligan LM, Kwok JB, Healey CS, et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363: 458–60.
Donis-Keller H, Dou S, Chi D, et al. Mutations in RET protooncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2: 851–6.
Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999, 17: 380–93.
Schuffenecker I, Billaud M, Calender A, et al. RET proto-oncogene mutations in French MEN 2A and FMTC patients. Hum Mol Genet 1994, 3: 1939–43.
Frank-Raue K, Hoppner W, Frilling A, et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: Relation between genotype end phenotype. J Clin Endocrinol Metab 1996, 81: 1780–3.
Mulligan LM, Eng C, Healey CS, et al. Specific mutations of the RET protooncogene are related to disease phenotype in MEN 2A and FMTC. Nat Genet 1994, 6: 70–4.
Mulligan LM, Marsh DJ, Robinson BG, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995, 238: 343–6.
Eng C, Clayton D, Schuffenecker I, et al. The relation between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplaia type 2: international RET Mutation Consortium analysis. JAMA 1996, 276: 1575–9.
Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86: 5658–71.
Pichel JG, Shen L, Sheng HZ. Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 1993, 363: 458–60.
Sanchez MP, Silos-Santiago I, Frisen J, He B, Lira SA, Barbacid M. Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 1996, 382: 70–3.
Eng C. RET proto-oncogene in the development of human cancer. J Clin Onc 1999, 17: 380–93.
Klein RD, Sherman D, Ho WH, et al. A gpi-linked protein that interacts with ret to form a candidate neurturin receptor. Nature 1998, 392: 210–3.
Hofstra RM, Landsvater RM, Ceccherini I, et al. A mutation in the RET proto-oncogene associated with endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367: 375–6.
Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullarythyroid carcinoma. Clin Endocrinol (Oxf) 2004, 61: 299–310.
Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Intern Med 2003, 253: 616–26.
Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C. Somatic and MEN 2A de novo mutations identified in the RET protooncogene by screening of sporadic MTC: s. Hum Mol Genet 1994, 3: 1259–62.
Wohllk N, Cote GJ, Bugalho MM, et al. Relevance of RET protooncogene mutations in sporadic medullarythyroid carcinoma. J Clin Endocrinol Metab 1996, 81: 3740–5.
Conte-Devolx B, Schuffenecker I, Niccoli P, et al. multiple endocrine neoplasia type 2: management of patients and subjects at risk. French Study Group on Calcitonin-Se-creting Tumors (GETC). Horm Res 1997, 47: 221–6.
Lallier M, St-Vil D, Giroux M, et al. Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome. J Pediatr Surg 1998, 33: 846–8.
Lips CJ. Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on multiple Endocrine Neoplasia and von Hippel-Lindau disease. J Intern Med 1998, 243: 589–94.
Wells SA Jr, Skinner MA. Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998, 106: 29–34.
Vieira AE, Mello MP, Elias LL, et al. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A. Horm Metab Res 2002, 34: 202–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Erdogan, M.F., Gürsoy, A., Özgen, G. et al. Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study. J Endocrinol Invest 28, 806–809 (2005). https://doi.org/10.1007/BF03347570
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03347570